GlassScriptPhysician profile
Sanatkumar Chetan Shroff
NPI 1144213745
$15,602.82
in general payments reported to CMS, 2019-2025
51 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,544 · 2020: $1,698 · 2021: $2,262 · 2022: $2,581 · 2023: $2,284 · 2024: $2,489 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,406 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,405.60 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,741.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,627.29 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,330.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,295.99 | 2019-2025 | |
| Lilly USA, LLC | $1,275.70 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $991.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.74 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $592.55 | 2021-2025 | |
| Amgen INC. | $575.66 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $530.66 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $483.61 | 2019-2025 | Trintellix |
| Allergan, INC. | $364.10 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $362.03 | 2019-2025 | Eliquis |
| Amarin Pharma, INC. | $298.36 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.86 | 2019-2025 | Xifaxan, Trulance |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $245.11 | 2019-2023 | Verquvo, Belsomra, Pneumovax 23 |
| Exact Sciences Corporation | $217.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $206.73 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Esperion Therapeutics, INC. | $194.50 | 2020-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $186.91 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $181.11 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $165.29 | 2019-2025 | |
| Boston Scientific Corporation | $156.79 | 2022-2024 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $154.31 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $146.34 | 2019-2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $124.49 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $114.60 | 2020-2024 | Contrave, Onzetra Xsail |
| Astellas Pharma US INC | $92.50 | 2023-2025 | Veozah, Myrbetriq |
| Phadia US INC. | $78.09 | 2024 | Immunocap |
| Seqirus USA INC | $68.95 | 2020-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Fluad |
| Dexcom, INC. | $63.86 | 2022-2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $60.94 | 2023-2024 | Belbuca, Xtampza |
| Almatica Pharma LLC | $59.33 | 2022 | |
| Biodelivery Sciences International, INC. | $54.42 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $52.63 | 2021 | |
| Redhill Biopharma INC. | $49.36 | 2021 | |
| Edwards Lifesciences Corporation | $44.66 | 2022-2024 | |
| Axsome Therapeutics, INC. | $38.17 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $38.02 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $35.70 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $34.27 | 2022 | |
| Cequr Corporation | $32.50 | 2022-2023 | Cequr Simplicity |
| Alkermes, INC. | $26.83 | 2023 | Vivitrol |
| Nevro Corp. | $21.52 | 2021 | |
| Hikma Pharmaceuticals USA | $21.15 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.85 | 2025 | Caplyta |
| Genentech USA, INC. | $19.50 | 2020 | |
| Eisai INC. | $18.65 | 2020 | |
| Acella Pharmaceuticals, LLC | $17.02 | 2025 | NP Thyroid 60 |
| Corcept Therapeutics | $16.34 | 2019 | |
| Horizon Therapeutics Plc | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanatkumar Shroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.